Avelumab in Patients With Relapsed or Recurrent Ovarian Cancer

July 2, 2015
Jeffrey Infante, MD

Jeffrey Infante, MD, director, Drug Development Program, Sarah Cannon Research Institute, discusses a phase Ib, open-label expansion trial examining avelumab for the treatment of patients with previously treated, recurrent or refractory ovarian cancer.